Literature DB >> 3624454

Antibodies in sera from patients with myasthenia gravis do not bind to nicotinic acetylcholine receptors from human brain.

P J Whiting, J Cooper, J M Lindstrom.   

Abstract

Nicotinic acetylcholine receptors (AChRs) from brains of chickens and rats have recently been purified and characterized (Whiting and Lindstrom, Biochemistry, 25 (1986) 2082-2093; J. Neurosci., 6 (1986) 3061-3069; Proc. Natl. Acad. Sci. U.S.A., 84 (1987) 595-599). Using both antisera and monoclonal antibodies prepared to AChRs from rat brain, we have demonstrated the existence of a homologous AChR in human brain. Here we report that antibodies to muscle AChRs in the sera of patients with myasthenia gravis (MG) do not bind to AChRs from human brain. Similarly, there was no binding of sera from patients with Guillain-Barré, amyotrophic lateral sclerosis, multiple sclerosis, or Lambert-Eaton myasthenic syndrome. Additionally, no binding of any of these sera to the alpha-bungarotoxin (alpha-Bgt) binding protein from human brain could be detected. This data is consistent with other data using antibodies to AChRs from muscle and nerve in demonstrating that the AChR in brain is antigenically distinct from the AChR in skeletal muscle AChR, and, together with the lack of central neurological symptoms in MG, suggests that the low concentrations of anti-AChR antibodies in the cerebrospinal fluid of MG patients do not bind to AChRs in brain.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3624454     DOI: 10.1016/0165-5728(87)90075-0

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  Neuronal-type alpha-bungarotoxin receptors and the alpha 5-nicotinic receptor subunit gene are expressed in neuronal and nonneuronal human cell lines.

Authors:  B Chini; F Clementi; N Hukovic; E Sher
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

2.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

Review 3.  Desensitization of central cholinergic mechanisms and neuroadaptation to nicotine.

Authors:  E L Ochoa; L Li; M G McNamee
Journal:  Mol Neurobiol       Date:  1990 Fall-Winter       Impact factor: 5.590

Review 4.  Nicotinic acetylcholine receptors in health and disease.

Authors:  J Lindstrom
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

Review 5.  Molecular studies of the neuronal nicotinic acetylcholine receptor family.

Authors:  J Lindstrom; R Schoepfer; P Whiting
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

Review 6.  The neuronal nicotinic acetylcholine receptor in some hereditary epilepsies.

Authors:  F J Barrantes; E Aztiria; M B Rauschemberger; A Vasconsuelo
Journal:  Neurochem Res       Date:  2000-05       Impact factor: 3.996

Review 7.  Pain, Headache, and Other Non-motor Symptoms in Myasthenia Gravis.

Authors:  Olivia Tong; Leslie Delfiner; Steven Herskovitz
Journal:  Curr Pain Headache Rep       Date:  2018-05-03

8.  Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?

Authors:  Jindrich Soltys; Bendi Gong; Henry J Kaminski; Yuefang Zhou; Linda L Kusner
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

9.  Profound olfactory dysfunction in myasthenia gravis.

Authors:  Fidias E Leon-Sarmiento; Edgardo A Bayona; Jaime Bayona-Prieto; Allen Osman; Richard L Doty
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

Review 10.  Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica.

Authors:  Zhen Wang; Yaping Yan
Journal:  Front Immunol       Date:  2017-12-12       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.